[go: up one dir, main page]

UY33382A - Compuestos heterocíclicos de nitrógeno insaturados útiles como inhibidores de pde10 - Google Patents

Compuestos heterocíclicos de nitrógeno insaturados útiles como inhibidores de pde10

Info

Publication number
UY33382A
UY33382A UY0001033382A UY33382A UY33382A UY 33382 A UY33382 A UY 33382A UY 0001033382 A UY0001033382 A UY 0001033382A UY 33382 A UY33382 A UY 33382A UY 33382 A UY33382 A UY 33382A
Authority
UY
Uruguay
Prior art keywords
nitrogen compounds
hiterocyclic
pde
insured
compounds useful
Prior art date
Application number
UY0001033382A
Other languages
English (en)
Inventor
Liu Qingyian
Zhong Wenge
Jennifer R Allen
Hu Essa
Robert M Rzasa
Michael J Frohn
Jian J Chen
Rumfelt Shannon
Alexander J Pickrell
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44278966&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY33382(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of UY33382A publication Critical patent/UY33382A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/15—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen containing halogen
    • C07C53/16—Halogenated acetic acids
    • C07C53/18—Halogenated acetic acids containing fluorine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/056—Ortho-condensed systems with two or more oxygen atoms as ring hetero atoms in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Diabetes (AREA)
  • Psychiatry (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se describen compuestos heterocíclicos de nitrógeno de la fórmula (I):(I), como se definen en la especificación, composiciones que los contienen, y procesos para preparar tales compuestos. También se proporcionan en la presente métodos para tratar trastornos o enfermedades tratables por inhibición de PDE10, tales como obesidad, enfermedad de Huntington, diabetes no dependiente a insulina, esquizofrenia, trastorno bipolar, trastorno obsesivo-compulsivo, y similares.
UY0001033382A 2010-05-13 2011-05-12 Compuestos heterocíclicos de nitrógeno insaturados útiles como inhibidores de pde10 UY33382A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US33452510P 2010-05-13 2010-05-13

Publications (1)

Publication Number Publication Date
UY33382A true UY33382A (es) 2011-10-31

Family

ID=44278966

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001033382A UY33382A (es) 2010-05-13 2011-05-12 Compuestos heterocíclicos de nitrógeno insaturados útiles como inhibidores de pde10

Country Status (26)

Country Link
US (3) US8957073B2 (es)
EP (1) EP2569300A1 (es)
JP (1) JP5702855B2 (es)
KR (1) KR101564806B1 (es)
CN (1) CN103221404B (es)
AR (1) AR081627A1 (es)
AU (1) AU2011253057B2 (es)
BR (1) BR112012029026A2 (es)
CA (1) CA2798490A1 (es)
CL (1) CL2012003178A1 (es)
CO (1) CO6630189A2 (es)
CR (1) CR20120635A (es)
EA (1) EA201291236A1 (es)
IL (1) IL222898A (es)
MA (1) MA34300B1 (es)
MX (1) MX2012013130A (es)
NZ (1) NZ603876A (es)
PE (1) PE20130576A1 (es)
PH (1) PH12012502212A1 (es)
SG (1) SG185515A1 (es)
TN (1) TN2012000530A1 (es)
TW (1) TW201206902A (es)
UA (1) UA109438C2 (es)
UY (1) UY33382A (es)
WO (1) WO2011143365A1 (es)
ZA (1) ZA201208510B (es)

Families Citing this family (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8497265B2 (en) * 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
NZ603876A (en) * 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
JP2013526537A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリールオキシカルボシクリル化合物
AU2011253143A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
BR112013021180A2 (pt) 2011-02-18 2019-09-24 Allergan Inc derivados de 6,7-dialcóxi-3-isoquinolinol substituído como inibidores de fosfodiesterase 10 (pde10a)
SI2718270T1 (sl) 2011-06-10 2022-11-30 Merck Patent Gmbh Sestavki in postopki za proizvodnjo pirimidinskih in piridinskih spojin z BTK inhibitorno aktivnostjo
US8623860B2 (en) * 2011-12-30 2014-01-07 Boehringer Ingelheim International Gmbh Azetidine derivatives, pharmaceutical compositions and uses thereof
TW201348231A (zh) 2012-02-29 2013-12-01 Amgen Inc 雜雙環化合物
WO2013169622A1 (en) * 2012-05-09 2013-11-14 Zoetis Llc Azetidine derivatives as antiparasitic agents
UY34858A (es) * 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10
WO2014071044A1 (en) 2012-11-01 2014-05-08 Allergan, Inc. Substituted 6,7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (pde10a)
MX2015007205A (es) 2012-12-06 2016-03-31 Quanticel Pharmaceuticals Inc Inhibidores de la desmetilasa de histona.
CA2900303A1 (en) * 2013-02-07 2014-08-14 Merck Patent Gmbh Substituted quinoxaline derivatives and their use as positive allosteric modulators of mglur4
US9200016B2 (en) 2013-12-05 2015-12-01 Allergan, Inc. Substituted 6, 7-dialkoxy-3-isoquinoline derivatives as inhibitors of phosphodiesterase 10 (PDE 10A)
PE20161384A1 (es) 2014-02-13 2016-12-28 Incyte Corp Ciclopropilaminas como inhibidores de lsd 1
ME03654B (me) 2014-02-13 2020-07-20 Incyte Corp Ciklopropilamini kao lsd1 inhibitori
WO2015123437A1 (en) 2014-02-13 2015-08-20 Incyte Corporation Cyclopropylamines as lsd1 inhibitors
US9493442B2 (en) 2014-02-13 2016-11-15 Incyte Corporation Cyclopropylamines as LSD1 inhibitors
EP3105216B1 (en) * 2014-02-14 2018-10-10 Takeda Pharmaceutical Company Limited Pyrazine modulators of gpr6
CN104016909B (zh) * 2014-04-03 2016-04-20 定陶县友帮化工有限公司 一种2-氨基-3-溴-5-氯吡啶的合成方法
CN104016911A (zh) * 2014-04-03 2014-09-03 定陶县友帮化工有限公司 一种2-氨基-3,5-二溴吡啶的合成方法
MX361606B (es) * 2014-05-19 2018-12-11 Merial Inc Compuestos antihelmínticos.
WO2016007736A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Imidazopyrazines as lsd1 inhibitors
WO2016007722A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
US9695168B2 (en) 2014-07-10 2017-07-04 Incyte Corporation Substituted imidazo[1,5-α]pyridines and imidazo[1,5-α]pyrazines as LSD1 inhibitors
WO2016007727A1 (en) 2014-07-10 2016-01-14 Incyte Corporation Triazolopyridines and triazolopyrazines as lsd1 inhibitors
ES2901114T3 (es) 2014-08-29 2022-03-21 Tes Pharma S R L Inhibidores de ácido alfa-amino-beta-carboximucónico semialdehído descarboxilasa
WO2016054560A1 (en) * 2014-10-02 2016-04-07 Flatley Discovery Lab Isoxazole compounds and methods for the treatment of cystic fibrosis
MX373154B (es) 2015-04-03 2020-04-22 Incyte Holdings Corp Compuestos heterocíclicos como inhibidores de demetilasa 1 específica de lisina (lsd1).
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
MX389824B (es) 2015-08-12 2025-03-20 Incyte Holdings Corp Sales de un inhibidor de dimetilasa 1 especifica para lisina (lsd1).
EP3445339B1 (en) 2016-04-22 2023-08-23 Incyte Corporation Formulations of an lsd1 inhibitor
US20200321533A1 (en) * 2016-05-24 2020-10-08 President And Fellows Of Harvard College Compounds for organic light emitting diode materials
WO2017210545A1 (en) 2016-06-02 2017-12-07 Cadent Therapeutics, Inc. Potassium channel modulators
MX387259B (es) 2016-12-16 2025-03-18 Pfizer Agonistas receptores de glp-1 y usos de los mismos
PL3571193T3 (pl) 2017-01-23 2022-04-25 Cadent Therapeutics, Inc. Modulatory kanału potasowego
CN106957300A (zh) * 2017-04-12 2017-07-18 苏州汉德创宏生化科技有限公司 抗肿瘤杂环药物中间体2‑(3‑氮杂环丁基）吡啶二盐酸盐的合成方法
EP3700935A4 (en) 2017-10-25 2021-08-04 University Of South Florida DRUG-INDUCED ACTIVATION OF THE REELIN SIGNALING SYSTEM
JP7217273B6 (ja) 2017-10-27 2024-02-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ピリジンカルボニル誘導体およびｔｒｐｃ６阻害剤としてのその治療的使用
CN109956931B (zh) * 2017-12-26 2021-07-16 迈第康(上海)生物医药科技有限公司 四氢吡咯类化合物、其制备方法、药物组合物及用途
RS63124B1 (sr) 2018-03-08 2022-05-31 Incyte Corp Aminopirazin diol jedinjenja kao pi3k-y inhibitori
TWI707683B (zh) 2018-06-13 2020-10-21 美商輝瑞股份有限公司 Ｇｌｐ－１受體促效劑及其用途
CN112566637B (zh) 2018-06-15 2023-11-14 辉瑞公司 Glp-1受体激动剂及其用途
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS
WO2020047198A1 (en) 2018-08-31 2020-03-05 Incyte Corporation Salts of an lsd1 inhibitor and processes for preparing the same
EP3860987B1 (en) 2018-10-02 2023-07-19 Syngenta Participations Ag Pesticidally active benzene- and azine-amide compounds
BR112021007552A2 (pt) 2018-10-22 2021-07-27 Cadent Therapeutics, Inc. formas cristalinas de moduladores de canal de potássio
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102150A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
MX2021006034A (es) * 2018-11-22 2021-09-21 Qilu Regor Therapeutics Inc Agonistas de glp-ir y usos de los mismos.
EP3888848A4 (en) 2018-11-26 2022-08-03 Kyocera Corporation GAS NOZZLE, METHOD OF MAKING A GAS NOZZLE AND PLASMA TREATMENT DEVICE
AU2019387370A1 (en) 2018-11-30 2021-06-10 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
TWI853009B (zh) 2019-03-29 2024-08-21 瑞士商先正達農作物保護公司 殺有害生物活性之二-醯胺化合物
JOP20210272A1 (ar) 2019-04-05 2023-01-30 Syngenta Crop Protection Ag مركبات دايازين - أميد نشطة بشكل مبيد للآفات
MA55587A (fr) 2019-04-11 2022-02-16 Syngenta Crop Protection Ag Composés diazine-amide à action pesticide
PE20220143A1 (es) * 2019-04-12 2022-01-27 Qilu Regor Therapeutics Inc Agonistas de glp-1r y usos de los mismos
US10954221B2 (en) 2019-04-12 2021-03-23 Qilu Regor Therapeutics Inc. GLP-1R agonists and uses thereof
EP3972596B1 (en) * 2019-05-20 2025-07-16 Pfizer Inc. Combinations comprising benzodioxol as glp-1r agonists for use in the treatment of nash/nafld and related diseases
WO2021037614A1 (en) 2019-08-23 2021-03-04 Syngenta Crop Protection Ag Pesticidally active pyrazine-amide compounds
EP4028013A4 (en) * 2019-09-12 2023-10-18 Disarm Therapeutics, Inc. MRSA1 INHIBITORS
KR20250155067A (ko) 2019-10-25 2025-10-29 길리애드 사이언시즈, 인코포레이티드 Glp-1r 조절 화합물
PE20221422A1 (es) * 2019-11-15 2022-09-20 Ildong Pharmaceutical Co Ltd Agonista del receptor glp-1 y uso de este
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
WO2021154796A1 (en) 2020-01-29 2021-08-05 Gilead Sciences, Inc. Glp-1r modulating compounds
UA129481C2 (uk) * 2020-03-18 2025-05-07 Елджі Кем, Лтд. Агоніст рецептора glp-1, фармацевтична композиція, що його містить, та спосіб її отримання
EP4119555A4 (en) * 2020-03-18 2023-08-23 Lg Chem, Ltd. GLP-1 RECEPTOR AGONIST, PHARMACEUTICAL COMPOSITION THEREOF AND PROCESS FOR MANUFACTURE THEREOF
EP4196118A1 (en) 2020-08-13 2023-06-21 Boehringer Ingelheim International GmbH Treatment of cognitive impairement associated with schizophrenia
CN116348108A (zh) 2020-10-13 2023-06-27 勃林格殷格翰国际有限公司 再加工方法
US20240016959A1 (en) * 2020-11-19 2024-01-18 Cerecin Inc. Radiopharmaceutical ketone and dual tracer imaging in alzheimer's disease, cognitive impairment, and other conditions of altered cerebral metabolism
EP4247804A1 (en) 2020-11-20 2023-09-27 Gilead Sciences, Inc. Polyheterocyclic glp-1 r modulating compounds
US12264149B2 (en) 2020-12-30 2025-04-01 Tyra Biosciences, Inc. Indazole compounds as kinase inhibitors
US12180197B2 (en) 2021-03-11 2024-12-31 Gilead Sciences, Inc. GLP-1R modulating compounds
WO2022241287A2 (en) 2021-05-13 2022-11-17 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
BR112023025644A2 (pt) 2021-06-09 2024-02-27 Syngenta Crop Protection Ag Compostos de diazina-amida pesticidamente ativos
IL308122A (en) * 2021-06-16 2023-12-01 Celgene Corp Azetidinyl compounds consisting of a carboxylic acid group for the treatment of neurodegenerative diseases
BR112023026747A2 (pt) 2021-06-18 2024-03-12 Aligos Therapeutics Inc Métodos e composições para direcionamento de pd-l1
MX2024003872A (es) 2021-09-27 2024-04-19 Terns Pharmaceuticals Inc Acidos carboxilicos de benzimidazol como agonistas de glp-1r.
AU2022375634A1 (en) 2021-10-25 2024-06-06 Terns Pharmaceuticals, Inc. Compounds as glp-1r agonists
CN119212987A (zh) 2021-12-16 2024-12-27 安力高医药股份有限公司 用于靶向pd-l1的方法和组合物
IL315151A (en) 2022-02-23 2024-10-01 Terns Pharmaceuticals Inc Compounds as glp-1r agonists
TWI866545B (zh) * 2022-10-20 2024-12-11 南韓商東亞Ｓｔ股份有限公司 氮雜環丁烷基苯并唑化合物及其等作為mer及axl抑制劑的用途
KR20250166323A (ko) 2023-04-07 2025-11-27 테른스 파마슈티칼스, 인크. 간 장애 또는 심장대사 질환의 치료에 사용하기 위한 thr베타 효현제 및 glp-1r 효현제를 포함하는 조합
WO2025147609A1 (en) * 2024-01-05 2025-07-10 Dewpoint Therapeutics, Inc. Amino quinoline compounds and uses thereof

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
PT72878B (en) 1980-04-24 1983-03-29 Merck & Co Inc Process for preparing mannich-base hydroxamic acid pro-drugs for the improved delivery of non-steroidal anti-inflammatory agents
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
HN2002000266A (es) 2001-09-24 2003-11-16 Bayer Corp Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
SI2527315T1 (sl) * 2002-05-31 2014-06-30 Proteotech Inc., Spojine, sestavki in metode za zdravljenje amiloidnih bolezni in sinukleinopatij, kot so Alzheimerjeva bolezen, diabetes tipa 2 in Parkinsonova bolezen
PL377215A1 (pl) 2002-10-17 2006-01-23 Amgen Inc. Pochodne benzimidazolu oraz ich zastosowanie w charakterze ligandów receptora waniloidowego
EP1651251A4 (en) 2003-07-31 2008-06-18 Bayer Pharmaceuticals Corp METHOD FOR THE TREATMENT OF DIABETES AND RELATED DISEASES USING PDE 10A INHIBITORS
GB0325287D0 (en) * 2003-10-29 2003-12-03 Merck Sharp & Dohme Therapeutic agents
CN1984901B (zh) * 2004-05-18 2011-02-09 先灵公司 用作pde4抑制剂的取代的2-喹啉基-*唑
US20060019975A1 (en) 2004-07-23 2006-01-26 Pfizer Inc Novel piperidyl derivatives of quinazoline and isoquinoline
US20070072908A1 (en) * 2005-06-08 2007-03-29 Japan Tobacco Inc. Heterocyclic compounds
US7709501B2 (en) * 2005-12-23 2010-05-04 Amgen Inc. Vanilloid receptor ligands and their use in treatments
CA2635439A1 (en) 2006-01-27 2007-08-02 Pfizer Products Inc. Aminophthalazine derivative compounds
BRPI0821676A2 (pt) * 2007-12-21 2015-06-16 Astrazeneca Ab Composto, composição farmacêutica, e, processo para a preparação dos compostos.
BRPI0914891A2 (pt) 2008-06-20 2015-11-24 Metabolex Inc agonistas de aril gpr119 e usos dos mesmos
US20100041663A1 (en) * 2008-07-18 2010-02-18 Novartis Ag Organic Compounds as Smo Inhibitors
US20100204265A1 (en) 2009-02-09 2010-08-12 Genelabs Technologies, Inc. Certain Nitrogen Containing Bicyclic Chemical Entities for Treating Viral Infections
WO2010130424A1 (en) 2009-05-12 2010-11-18 Ortho-Mcneil-Janssen Pharmaceuticals, Inc 1,2,3-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders
JP5696856B2 (ja) 2009-09-03 2015-04-08 バイオエナジェニックス Ｐａｓｋの阻害用複素環式化合物
AU2010296420A1 (en) 2009-09-16 2012-03-22 Astellas Pharma Inc. Glycine compound
AU2011253143A1 (en) 2010-05-13 2012-12-06 Amgen Inc. Nitrogen- heterocyclic compounds as phosphodiesterase 10 inhibitors
JP2013526537A (ja) 2010-05-13 2013-06-24 アムジエン・インコーポレーテツド Ｐｄｅ１０阻害剤としてのヘテロアリールオキシカルボシクリル化合物
US8497265B2 (en) 2010-05-13 2013-07-30 Amgen Inc. Heteroaryloxyheterocyclyl compounds as PDE10 inhibitors
NZ603876A (en) * 2010-05-13 2015-02-27 Amgen Inc Nitrogen heterocyclic compounds useful as pde10 inhibitors
UY34858A (es) 2012-06-14 2013-11-29 Amgen Inc Compuestos de azetidina y piperidina útiles como inhibidores de pde10

Also Published As

Publication number Publication date
CN103221404A (zh) 2013-07-24
PH12012502212A1 (en) 2013-02-04
US20110306587A1 (en) 2011-12-15
EP2569300A1 (en) 2013-03-20
EA201291236A1 (ru) 2013-11-29
CN103221404B (zh) 2015-12-16
US9718803B2 (en) 2017-08-01
US20160102075A1 (en) 2016-04-14
WO2011143365A1 (en) 2011-11-17
ZA201208510B (en) 2017-11-29
NZ603876A (en) 2015-02-27
KR20130065666A (ko) 2013-06-19
AR081627A1 (es) 2012-10-10
AU2011253057B2 (en) 2014-11-20
CL2012003178A1 (es) 2013-07-05
US20140213572A1 (en) 2014-07-31
TW201206902A (en) 2012-02-16
MX2012013130A (es) 2013-04-11
US8957073B2 (en) 2015-02-17
SG185515A1 (en) 2012-12-28
MA34300B1 (fr) 2013-06-01
JP2013526536A (ja) 2013-06-24
AU2011253057A1 (en) 2012-11-29
CR20120635A (es) 2013-01-30
IL222898A (en) 2015-11-30
TN2012000530A1 (en) 2014-04-01
IL222898A0 (en) 2012-12-31
KR101564806B1 (ko) 2015-10-30
PE20130576A1 (es) 2013-05-19
JP5702855B2 (ja) 2015-04-15
CO6630189A2 (es) 2013-03-01
CA2798490A1 (en) 2011-11-17
BR112012029026A2 (pt) 2016-08-02
UA109438C2 (uk) 2015-08-25

Similar Documents

Publication Publication Date Title
UY33382A (es) Compuestos heterocíclicos de nitrógeno insaturados útiles como inhibidores de pde10
CO6382157A2 (es) Compuestos pirazina como inhibidores de fosfodiesterasa 10
UA113051C2 (xx) Гетероциклічні похідні та їх застосування у лікуванні неврологічних розладів
NZ705135A (en) Heteroaryl compounds and methods of use thereof
TN2010000167A1 (en) Organic compounds
UY32848A (es) Compuestos heterocíclicos de oxima
UY33587A (es) Nuevos compuestos como inhibidores de quinasas syk y jak
ECSP13012611A (es) Derivados de pirazol-aminopirimidina como moduladores de la lrrk2
UY33817A (es) ?nuevas oxindolpirimidinas bencílicas?.
CR11207A (es) Compuestos organicos
UY34955A (es) 4-metil-2,3,5,9,9b-pentaaza-ciclopenta[a]naftalenos
CR20120264A (es) Compuestos
BR112012029647A2 (pt) novos derivados de pirimidinas
CO7350641A2 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados
ECSP11011558A (es) Nuevos compuestos químicos.
MX2010005649A (es) Compuestos novedosos como ligandos del receptor canabinoide y sus usos.
UY32744A (es) Derivados de 2-carboxamida-7-piperazinil-benzofurano 774
GB201114389D0 (en) Novel compounds
MX2014005538A (es) 1-piridazinil-hidroxiimino-3-fenil-propanos como agonistas de proteina g-receptor acoplado a acido biliar 1 (gpbar1).
BR112012032235A2 (pt) 3-oxo-3,9-diidro-1h-cromeno[2,3-c]pirróis como ativadores de glicoquinase
PH12014502780A1 (en) Azetidine and piperidine compounds useful as pde10 inhibitors
CA2863110A1 (en) 1,2- pyridazine, 1,6- pyridazine or pyrimidine - benzamide derivatives as gpbar1 modulators
MX2014004853A (es) 1-cicloalquil- o 1-heterociclil-hidroxiimino-3-fenil-propanos.
HK1176618A (en) Nitrogen heterocyclic compounds useful as pde10 inhibitors

Legal Events

Date Code Title Description
109 Application deemed to be withdrawn

Effective date: 20200527